Introduction
Several lines of evidence implicate the insulin-like growth factor 1 receptor (IGF-1R) in tumor transformation and development as well as in tumor cell survival. This tyrosine kinase receptor displays mitogenic, transforming and antiapoptotic properties (Baserga, 1995 (Baserga, , 1999 Baserga et al., 1997; Le Roith et al., 1999; Girnita et al., 2003 Girnita et al., , 2005b Ahlen et al., 2005) . Previous studies suggest that the antiapoptotic function of IGF-1R mediates decreased sensitivity to chemotherapeutic drugs in vitro and in vivo. Moreover, the different strategies of inhibition IGF-1R expression or function resulted in blocking of tumor growth and metastasis and enhanced sensitivity to cytostatic drugs and irradiation (Baserga, 1995 (Baserga, , 2000 Yu and Rohan, 2000) . Targeting IGF-IR results in chemosensitization of sarcomas to conventional cytotoxic drugs, including doxorubicin and vincristine (Scotlandi et al., 2005) and blocking of IGF-1 signaling conferred sensitivity to the growth-inhibitory actions of trastuzumab in a model system (Lu et al., 2004) .
On the other hand, IGF-1R is not absolutely necessary for normal growth (LeRoith et al., 1995; Yu and Rohan, 2000) . Thus the IGF-1R is a highly promising anticancer treatment target.
The IGF-1R consists of two extracellular a-subunits with a ligand-binding domain, and two b-subunits involving a transmembrane domain, an intracellular tyrosine kinase domain and a C-terminal domain (LeRoith et al., 1995) . Receptor interaction with its specific ligand IGF-1 results in phosphorylation of tyrosine residues in the tyrosine kinase domain of the b-subunit. In turn, phosphorylation of the adaptor proteins insulin receptor substrate 1-4 and Shc leads to activation of distinct intracellular signaling pathways such as phosphatidyl inositol-3 kinase, the mitogenactivated protein kinase and the 14-3-3 pathways (Baserga, 1995 (Baserga, , 2000 LeRoith et al., 1995; Yu and Rohan, 2000) , which in turn exert pleiotropic effects.
The importance of IGF-1R in human cancer has raised therapeutic possibilities (Rohlik et al., 1987; Adams et al., 2000; Brodt et al., 2000; Girnita et al., 2000b; Kanter-Lewensohn et al., 2000; Navab et al., 2001 ; All-Ericsson et al., 2002; Larsson et al., 2005) . We recently demonstrated that the cyclolignan PPP specifically inhibits the IGF-1R activity , where it did not inhibit the highly homologous insulin receptor . In IGF-1R-positive tumor cells, PPP induced apoptosis and reduced cell survival with IC 50 values in the range of 0.05-0.5 mM Vasilcanu et al., 2004; Catrina et al., 2005; Menu et al., 2005; Stromberg et al., 2005; Ulfarsson et al., 2005) . Furthermore, PPP caused complete regression of solid tumors in xenografted mice as well it strongly decreased the tumor burden and significantly prolonged survival of mice in multiple myeloma 5T33MM mouse model (Menu et al., 2005) .
In the perspective of using PPP, or related compounds in cancer therapy, it is important to investigate whether serious resistance to it can be developed in malignant cells. Accordingly, we now sought to establish PPP resistance and to characterize the obtained resistance regarding kinetics and extent, as well as to evaluate responsiveness to cytostatic drugs. We also tried to approach the underlying mechanisms.
Results

Establishment of PPP-resistant cell lines
Ten human tumor cell lines (see Table 1 ), with established IGF-1R expression and dependence, were subjected to selection for PPP resistance to PPP by gradually increasing the concentrations, starting with 1 nM, over an 80-week period. Only four cell lines could develop some kind of resistance, whereas all others died within a couple of weeks. With the exception of Line 7 (which did not tolerate higher concentration than 0.02 mM), they developed further resistance to PPP. This occurred fastest in Line 2 cells that after 6 months could grow at a PPP concentration of 0.1 mM, whereas Line 1 and Line 3 needed almost 9 months to reach this resistance level (Figure 1a ). The PPP concentration could not be further increased in Line 1 cells and after 2 months in the presence of 0.1 mM PPP they died ( Figure 1a) . Line 3 cells managed to survive in 0.1 mM PPP but could not tolerate an increase to 0.2 mM before the 70th week. They remained at this level until the end point of the study (80th week). Line 2, on the other hand, could make an increase to 0.2 mM at 40 weeks. From this level they tolerated a rapid increase to 0.4 mM within a few weeks. After achieving this level of resistance, no further dose increment could be made until week number 70 (to 0.5 mM) and at the end point the Line 2 Res cells were still growing in the presence of 0.5 mM PPP (Figure 1a) . Line 2 and Line 3 cells that survived the selection process are from now denoted as Line 2Res and Line 3Res (Res ¼ PPP resistant) followed by actual PPP concentration (e.g. Line 2Res0.5).
We now investigated the dose-response effects of PPP on resistant cell lines regarding cell survival. Line 3Res0.1, Line 2Res0.5, Line 3Res0.1 and Line 3Res0.2 cells were exposed to different concentrations of PPP (0.05-5 mM) for 72 h and analysed for survival compared to non-resistant parental cells. As shown in Figure 1b parental cell lines responded adequately to PPP with IC 50 values of around 0.05 and 0.1 mM, respectively. The resistant cells, of course, tolerated the PPP concentrations they were resistant to, but further increase resulted in strong responses comparable to the parental cells ( Figure 1b ). This means that the resistant cells had not acquired any tolerance for higher PPP doses than those they had been selected for. Similarly, we investigated sensitivity to PPP regarding apoptotic cell death using Annexin V (AV) staining. In parental Line2 cells, there was a basal apoptotic rate of o1% (Figure 1c ). This was dose-dependently increased by PPP. A PPP dose of 0.5 mM increased apoptotic rate more than fourfold. In Line2Res0.5 cells, whose basal apoptotic rate was around 2.5%, 0.5 mM PPP had, as expected, no additional effects, but when treated with a concentration of 2.5 mM there was an increase in numbers of apoptotic cells (Figure 1c ). Line3Res cells were responsive to both 0.5 and 2.5 mM PPP regarding apoptosis (Figure 1c ).
Sampling of cells for biochemical, molecular and cytogenetic analyses
Analyses of various intracellular events in relationship to resistance development were carried out on Line 2Res and Line 3Res cells. As indicated in Figure 2a and b, the analyses were performed at different resistance levels or time points.
Effect on drug resistance proteins (MDR1 and MRP1) and response to cytostatics MDR1 (ABCB1) and MRP1 (ABCC1) are the most commonly expressed drug resistance proteins or transporter proteins as a response to drug exposition (Gottesman et al., 2002) . The expression of MDR 1 and MRP1 was determined by Western blotting for parental Line 2 and Line 3 and resistant Line 2Res0.1-0.5 and Line 3Res0.1 and 0.2. Regarding MRP1 we could not detect any expression at all neither in the parental cells nor in the resistant ones (data not shown). On the other hand, MDR1 was expressed in both parental cells but there was no increase in its expression in any of the resistant cell lines (Figure 3a) .
We also investigated the resistant cells for sensitivity for cytostatic drugs. Line 2Res0.1, Line 2Res0.5, Figure 3b . Line 2Res0.1 and 0.5 cells are both highly more sensitive to cisplatin and doxorubicin compared to parental cells. Even in the case of treatment with mitomycin the Line 2Res0.5 cells were multifold (>100) more sensitive than the parental Line 2 cells (Table 2) . Regarding camptothecine, etoposide and 5-FU the resistant cells responded equally to parental Line 2 cells. Resistant Line 3 cells were slightly more sensitive to camptothecine, doxorubicin and 5-FU compared to the parental counterparts and responded equally to the other cytostatics ( Figure 3b and Table 2 ). In conclusion, none of the PPP-resistant cell lines showed reduced sensitivity to the investigated cancer drugs.
Analysis of IGF-1R expression and activity
As PPP is targeting the IGF-1R function, we investigated whether IGF-1R overexpression could be the Figure 4a and b show the quantified expression data as in relation to the level of resistance. In both resistant cell lines, there was a gradual increase in both mRNA and protein expression of IGF-1R. These increases reached a maximal magnitude being 2.5-3.5-fold higher than that of the parental cells. This maximal level of expression was reached at 0.1 mM PPP in both cell lines. In Line 2Res, this expression level remained up to a resistance level of 0.3 mM PPP, after which the IGF-1R mRNA and protein expression dropped to the levels equal to the parental cells ( Figure 4a ). In Line 3Res cells, the levels of IGF-1R transcript and protein were normalized at 0.2 mM ( Figure 4b ). We investigated whether the increased levels of IGF-1R transcripts were caused by stabilization of mRNA. This experiment was performed by treating the cells with the RNA polymerase inhibitor Actinomycin D (AD) (10 mM) for 6 or 9 h before analysis of IGF-1R mRNA levels. Because de novo transcription is completely blocked during these periods, the detected amounts of IGF-1R transcripts will be due to the rate of mRNA degradation (Nair et al., 2001) . Cells at resistance levels of 0.04 and 0.1 mM were used in these experiments. At these levels, the IGF-1R transcripts were increased 2 and 2.5-fold, respectively (Figure 4a and b) . As seen in Figure 4c Line 2Res and Line 3Res cells exhibited an increased degradation of IGF-1R mRNA compared to the parental cells. The difference was largest in the Line 2 cultures, in which the wild-type cells showed a very low degradation of IGF-1R mRNA at 6 and 9 h (histogram panels of Figure 4c ). Taken together with the data presented in Figure 4a and b, these data suggest that the temporary increase in IGF-1R transcripts in PPP-resistant cells was due to increased transcription of the IGF-1R gene. We also investigated whether there is any difference in responsiveness of IGF-1-stimulated IGF-IR phosphorylation at different PPP concentrations. Line 2Res0.5 and Line 3Res0.2, in comparison with parental cells, were serum-starved and treated with PPP and finally stimulated with IGF-1. Figure 5 shows the blots after detection of immunoprecipitated IGF-1R with a phosphotyrosine antibody. None of the cell lines showed any detectable IGF-1R phosphorylation in the absence of IGF-1, but responded to addition of the ligand. When treated with PPP (0.05-2.5 mM) there was a dosedependent decrease in activity. The pattern was similar for all cell lines, and optical density analyses of several different experiments did not reveal any essential differences between resistant and wild-type cell lines (data not shown). Thus, the responses to PPP regarding ligand-induced IGF-1R phosphorylation were not altered in the PPP tolerating cells.
Cytogenetic analyses of parental and PPP-resistant cells
To study IGF-1R, dual-color fluorescence in situ hybridization (FISH) was then performed on parental and resistant cells of both lines using BAC clones covering the IGF-1R locus (Figure 6a ). The results demonstrated that IGF-1R was not amplified or structurally rearranged in either of the resistant cell lines (Figure 6b ). 
Discussion
As the IGF-1R is generally established as a therapeutic target in cancer, a lot of attempts have been made to target and inactivate it. Among these neutralizing antibodies (Van Wyk et al., 1985; Sachdev et al., 2003) , dominant-negative receptors (Reinmuth et al., 2002) , antisense strategies (Resnicoff et al., 1994) , et al., 1996) and RNA interference (Bohula et al., 2003) can be mentioned. All of these approaches have shown excellent efficacies in experimental models. However, all of them more or less suffer from the fact that they are difficult to deliver in patients to obtain efficient target recognition in all tumor cells. From this point of view IGF-1R targeting using small molecules would be a much better choice in a clinical setting. Small molecular compounds usually exhibit a good bioavailability. However, in the approach of targeting the IGF-1R they may face the problem to crossreact with the highly homologous insulin receptor. In order to solve this problem crystallographic studies of the tyrosine kinase domain of the IGF-IR have been performed (Favelyukis et al., 2001; Pautsch et al., 2001) . Such studies may reveal subtle structural difference between the kinases of the two receptors and this way enable the design and production of small molecules acting as specific antagonists for the IGF-1R and therewith inhibiting its antiapoptotic effects (De Meyts and Whittaker, 2002) .
Tyrphostins belong to series of protein tyrosine kinase inhibitors being derived from the benzylidene malononitrile nucleus, resembling the phenolic group of tyrosine, with additional substitutions directed to increase their biological activity. Some of these substitutions resulted in significant discrimination among tyrosine kinases of particular growth factors. Some of them have shown semiselective inhibitory effects on the IGF-1R (Parrizas et al., 1997) . Tyrphostins targeting the substrate of the IGF-1R kinase have also been identified and exhibited a higher selectivity for IGF-1R than earlier compounds (Blum et al., 2000) . Because these tyrphostins were not stable enough catechol bioisosteres of them was produced. These tyrphostin derivatives were confirmed to inhibit IGF-1R phosphorylation and blocked formation of tumor cell colonies in soft agar (Blum et al., 2003) .
Recently, IGF-1R tyrosine kinase inhibitors based on pyrrolo-pyrimidines were reported (Garcia-Echeverria et al., 2004; Mitsiades et al., 2004) . In cell systems, they exhibited a 27-fold selectivity to the IGF-1R compared Limited resistance to PPP D Vasilcanu et al to the insulin receptor. They inhibited tumor cell growth both in cultures and in xenografts (Garcia-Echeverria et al., 2004; Mitsiades et al., 2004) .
The cyclolignan PPP, reported by us, seems to inhibit the receptor tyrosine kinase by interfering with a tyrosine residue in the activation loop of the kinase (Vasilcanu et al., 2004) . Whether PPP is interfering directly with the IGF-1R kinase or with IGF-1R-associated molecules or events is, however, still unknown. Most interestingly, PPP causes complete regression of various types of human solid malignancies (breast cancer, prostate cancer and malignant melanoma and Ewing's sarcoma) in animal models . Further, it substantially reduced the tumor burden and highly significantly prolonged animal survival in the multiple myeloma 5T33MM mouse model 5T33MM (Menu et al., 2005) . Very recently it was demonstrated that PPP drastically reduced the incidence of liver metastasis in mice xenografted with melanoma (Girnita et al., 2005a) .
Hence, it is highly probable that small molecular based IGF-1R inhibitors will have a place in future treatment of cancer. However, a very important and general drawback with cancer drugs, also concerning targeting with small molecules and antibodies (Chen et al., 2004; Jones et al., 2004; Nagata et al., 2004; Peggs, 2004) , is the generation of drug resistance (Longley and Johnston, 2005) . For this reason, we found it highly relevant to investigate whether resistance to PPP may occur after long-term treatment in a cellular context, as well as to characterize the obtained resistance. We can conclude that the development of resistance or tolerance to PPP is a very slow process. Starting with several malignant cell lines, well established in our lab for their IGF-1R expression and dependency, only two of them were able to develop some resistance. In particular, the obtained resistance was very limited. This was not only for the reason that the resistant cells did not tolerate higher PPP concentrations than 0.2 and 0.5 mM, but mainly that further addition of PPP caused massive cell death in the resistant cells. This means that the resistant cells have kept their high responsiveness to PPP. It should also be added here that today, being 13 months after the end point of the study, both resistant cell lines are still unable to adapt to higher PPP concentrations than 0.2 and 0.5 mM as well as the high responsiveness to PPP is retained (data not shown).
The precise mechanisms underlying the PPP resistance were not aimed to be disclosed in the present study. We could observe a temporary and limited increase in IGF-1R expression during the first 40-50 weeks, but there were no rearrangements or amplifica- tion of the IGF-1R gene. The temporary increase in IGF-1R expression appeared to be due to an elevated transcription of the IGF-1R gene. Although the increase in IGF-1R expression was transient it might be an important event to make the cells competent to further selection. The enhanced IGF-1R transcription could be explained by the feedback mechanism, given the fact that ligand-induced IGF-1R activation inhibits the transcription of the IGF-1R gene whereas the stability of mRNA remains unaffected (Hernandez-Sanchez et al., 1997). Therefore, it is not surprising that inhibition of IGF-1R phosphorylation releases this feedback action. The mechanisms behind the further resistance development are still unknown. However, we did not found any evidence that the two resistant cell lines acquire any essential alteration in responsiveness to PPP regarding IGF-1-induced IGF-1R phosphorylation. Possible mechanisms could, for instance, be that cells acquire specific mutations or specific gene gains resulting in overexpression of some signaling molecules.
Further studies need to be performed to investigate these issues. We could confirm that the two multidrug proteins MDR1 and MRP1, otherwise being the two mostly expressed resistance or transporter proteins as response to drug expositions (Gottesman et al., 2002) , were not increased in any of the two cell lines at the end of the experiment. Furthermore, the PPP-resistant cells were either equally sensitive or more sensitive to investigated cytostatics. Actually, one of the resistant cell lines (Line 2Res), originated from malignant melanoma, exhibited a >10-fold increased sensitivity to cisplatin and were >100-fold more sensitive to doxorubicin and mitomycin compared to parental cells. It is well known that the IGF-1R makes tumor cells more resistant to different types of cancer drugs and that attenuation of IGF-1R activity increases the efficiency of them (Jerome et al., 2003; Ye et al., 2003; Alexia et al., 2004; Goetsch et al., 2005) . Apparently, this sensitizing effect of IGF-1R inhibition is not lost in PPP-resistant cells. It is well known that an increased level of IGF-IR signaling reduce sensitivity to chemotherapeutic drugs in vitro and in vivo. Thus, strategies that target IGF-IR signaling may prevent or delay development of resistance to chemotherapeutic drugs.
The present study addresses two major issues regarding resistance to IGF-1R inhibitors. Firstly, whether cancer cells may specifically develop resistance against PPP and, secondly, whether cancer cells may develop resistance against inhibitory targeting of IGF-1R in general. The absence of increased expression of MDR suggests that cancer cells do not produce a protective mechanism based on simple elimination of PPP. Absence of such mechanism is related probably to the chemical properties of PPP itself. However, there are several reports indicating that IGF-1R controls expression/function of MDR and several other resistance mechanisms resulting in increased resistance to cytostatic compounds (Hirsch-Ernst et al., 1995; Guo et al., 1998) . Consequently, an inhibitory targeting of IGF-1R in general would be free of several resistant mechanisms.
In conclusion, it is evident that malignant cells produce no (actually most cell types subjected to selection did not survive) or a remarkably weak resistance to the IGF-1R inhibitor PPP. As drug resistance causes treatment failure in 90% of patients with spread cancer (Longley and Johnston, 2005) , the property of PPP not to generate serious resistance to itself and crossresistance to chemotherapeutic drugs, in conjunction with its high efficacy in selectively erasing malignant IGF-1R expressing tumors in vivo, seems important and makes this group of substances especially interesting in the design of new effective anticancer agents.
Experimental procedures
Reagents PPP was synthesized as described (Buchardt et al., 1986) and following recrystallization its purity was 99.7%. For experimental purposes, PPP was dissolved in 0. 
Cell cultures and generation of PPP-resistant cells
Ten established human cancer cell lines were presented in the study (Table 1 ). All lines had established IGF-1R expression and dependency, and were responsive to PPP treatment with IC 50 s at less than 0.1 mM. The parental lines are denoted here as Line 1-10. Cells that survived the resistance selection are referred to as Line XResY (Y is resistance level in mM).
The cells were cultured in monolayers in standard media RPMI supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. In order to establish resistant subclones, cells were incubated with increased concentrations of PPP over an 80-week period. As a starting concentration of PPP, we used 0.001 mM (1 nM), which is around 50-fold lower than the IC 50 values for all these cell lines . The cells were considered resistant to a given concentration of PPP when we succeeded to culture them in two consecutive passages. Up to a PPP concentration of 0.1 mM, the concentrations were doubled at each increment (e.g. from 0.01 to 0.02 mM). After reaching a PPP concentration of 0.1 mM, the doses were increased by 0.1 mM for each step (like 0.2-0.3 mM).
Immunoprecipitation and Western blotting
For determination of IGF-1R phosphorylation cells were lyzed and subjected to immunoprecipitation by adding 20 ml of resuspended volume of the sepharose conjugate (Protein G Sepharose) and incubation at 41C with the anti-IGF-IR b-antibody H-60. Cell lysates or immunoprecipitates were resolved by sodium dodecyl sulfhate polyacrylamide gel electrophoresis (Laemmli, Limited resistance to PPP D Vasilcanu et al 1970), transferred onto nitrocellulose membranes (Hybond, Amersham, UK) and incubated with PY99 (for determination of phosphorylation), anti-IGF-1R b-subunit, or anti-MDR1or MRP1 antibodies for 1 h. This was followed by washes with phosphate-buffered saline and incubation with a biotinylated secondary antibody species specific (Amersham) for 1 h. After incubation with streptavidin-labeled horseradish peroxidase, the detection was made (Hyperlm-ECL, Amersham). The films were scanned by Fluor-S (BioRad) and the signals were quantied using Quantity One software (BioRad). Subsequent incubation with a b-actin antibody served as a loading control.
Analysis of IGF-1R mRNA expression by semiquantitative RT-PCR Total RNA was isolated from adherent cells, with or without pretreatment with AD, using RNeasy kit (Qiagen, Hilden, Germany). Five hundred nanogram total RNA was reverse transcribed to cDNA using random primers (Promega, Madison, WI, USA) in 20 ml reactions containing 500 mM dNTP (Invitrogen, Carlsbad, CA, USA) and using SuperScript II Reverse Transcriptase (Invitrogen). Amplification of IGF-1R was carried out using the primers IGF-1Rfwd (5 0 -GCC CGA AGG TCT GTG AGG AAG AA-3 0 ) and IGF1Rrev (5 0 -GGT ACC GGT GCC AGG TTA TGA-3 0 ) (Girnita et al., 2000a) . The thermocycling conditions included an initial denaturation step at 941C; followed by 29 step cycles of 941C for 30 s, 601C for 30 s and 721C for 1 min; and a nal elongation step at 701C for 7 min. Parallel amplification of b-actin was used as an internal control of RNA integrity and linearity in the PCR reaction, as well as a reference standard for semiquantitative assessment of IGF-1R mRNA expression levels. The PCR products were detected by ethidium bromide staining after separation in a 1% agarose gel and visualized in a Fluor-S MultiImager System (BioRad, Hercules, CA, USA) (Girnita et al., 2000a) .
Preparation of DNA and metaphase chromosomes Suspensions of parental and resistant Line 2 and Line 3 cells treated with different concentrations of PPP and consecutively stored at À1351C were thawed and recultured in the presence of PPP at the same concentration as for which the resistance was observed. After culturing for 3-5 days, the cells were harvested and used for DNA extraction as well as preparation of metaphase chromosomes using standard methods.
Fluorescence in situ hybridization FISH was performed on metaphase slides of parental Line 2 and Line 2Res (0.04, 0.1 and 0.4) cells, as well as on Line 3 and Line 3Res (0.04, 0.1 and 0.2) cells. Three BAC probes spanning the IGF-1R gene locus in 15q26.3 were used as probes. BAC DNA was isolated using the QIAGEN Plasmid Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions, and labeled by nick translation. The BAC RP11-631H11 was labeled with Texas Red-5-dUTP (NEN Life Science, Boston, MA, USA), and RP11-262P8 and RP11-654A16 were labeled with fluorescein-12-dUTP (FITC; NEN Life Science, Boston, MA). The accuracy and specificity of all three BAC clones were confirmed by hybridization onto normal human metaphase chromosomes (Vysis, Inc., Downers Grove, IL, USA).
Dual-color FISH was performed using standard methods as previously described (Yang et al., 2002) . In brief, the metaphase slides were denatured in 70% formamide/2 Â SSC (pH 7.0) at 721C for 2 min, followed by dehydration in 70, 85, and 100% ethanol for 2 min each. The hybridization mixture, containing 10 ng/ml of each of the labeled probes 631H11, 262P8 and 654A16, was denatured for 7 min at 801C and co-hybridized onto metaphase slides of each cell line. The results were analysed in a Zeiss Axioplan 2 imaging epifluorescence microscope (Carl Zeiss Jena GmbH, Jena, Germany), and documented using the Metasystems Isis imaging system (Metasystems, Altlussheim, Germany). A total of 50 metaphases were scored for each cell line.
Cell viability and apoptosis assays
Cell viability was assessed in triplicates by the Cell Proliferation kit II (XTT) (Roche, Mannheim, Germany), which is based on the colorimetric change of the yellow tetrazolium salt XTT to orange formazan dye by the respiratory chain of viable cells . All standards and experiments were performed in triplicates.
Apoptosis was quantified by FACS after staining with AV-fluorescein isothiocyanate (FITC) and propidium iodide (PI) using TACSt Annexin V-FITC Apoptosis Detection Kit (R&D Systems).
